Selexipag: 8 agencies, 2016–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where selexipag met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 8.1 years, from 2016 at PBAC (Australia) to 13 Aug 2024 at PHARMAC (New Zealand).
PBAC (Australia) changed its position: not recommended in 2016, recommended by 2020, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for selexipag by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess selexipag, in 2016; PHARMAC (New Zealand) did not open a file until 13 Aug 2024 — an unusually long tail of 8.1 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed selexipag to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), AWMSG (Wales) and SMC (Scotland) among others.
2 of the 8 agencies here assessed selexipag more than once, PHARMAC (New Zealand) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for selexipag.
The full ledger for selexipag reads 5 recommended, 4 restricted, 1 other and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 13 Aug 2024 | Pulmonary arterial hypertension - monotherapy | PTAC advice: High | source |
| AOTMIT (Poland) | 4 Feb 2020 | programu lekowego „Leczenie tętniczego nadciśnienia płucnego (TNP) (ICD-10 I27, I27.0) | recommended conditionally | source |
| AWMSG (Wales) | 12 Jun 2018 | Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, ei… | recommended with restrictions (full) | source |
| SMC (Scotland) | 7 May 2018 | For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients in… | accepted (restricted) | source |
| PBAC (Australia) | 2017 | Selexipag is indicated for the treatment of idiopathic pulmonary arterial hypertension; heritable pulmonary arterial hypertension; pulmonary arterial | hypertension assoc… | Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Require… | source |
7 further decisions for selexipag, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- macitentan — divergent outcome (recommended vs restricted) on a shared indication
- rivaroxaban — same ATC class B01A — Antithrombotics
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
Coverage: 12 decisions for selexipag from 8 agencies, 2016 to 2024. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.